.After increasing $170 million back in February, metabolic disease-focused BioAge Labs has submitted to debut on the public market.The Eli Lilly-partnered biotech expect to list on the Nasdaq under the sign “BIOA,” depending on to records submitted along with the Stocks and Swap Compensation. The firm has not openly discussed an expected monetary quantity for the offering.The clinical-stage company promotes lead applicant azelaprag, a by mouth delivered little molecule slated to go into phase 2 testing in combo with semaglutide– sold by Novo Nordisk under brand name Wegovy for weight loss– in the 1st one-half of following year. Semaglutide is actually also offered as Ozempic as well as Rybelsus through Novo for diabetic issues.
Apelin receptor agonist azelaprag is designed to blend well with GLP-1 medications, boosting weight management while protecting muscle mass. The investigational medicine was actually discovered to be well-tolerated one of 265 individuals all over 8 phase 1 trials, depending on to BioAge.Earlier, BioAge got the help of Lilly to manage a test incorporating azelaprag with the Large Pharma’s GLP-1/ GIP receptor agonist tirzepatide, which is marketed for diabetic issues as Mounjaro and also Zepbound for fat burning. The companions are currently performing a period 2 trial of azelaprag and tirzepatide, along with topline outcomes assumed in the third quarter of 2025.The biotech is likewise intending a blood insulin sensitiveness proof-of-concept trial determining azelaprag as a monotherapy in the very first fifty percent of upcoming year to support prospective indication development.
In addition, the business organizes to talk to the FDA for authorization in the 2nd one-half of 2025 to introduce human testing for an NLRP3 prevention targeting metabolic diseases and also neuroinflammation.BioAge’s expected relocate to the public market observes a mild uptick in prepared biotech IPOs from Bicara Rehabs and also Zenas Biopharma. Zooming out, the latest IPO landscape is a “combined photo,” with high quality firms still debuting on everyone markets, simply in decreased amounts, according to PitchBook.